ETFOptimize | High-performance ETF-based Investment Strategies

Quantitative strategies, Wall Street-caliber research, and insightful market analysis since 1998.


ETFOptimize | HOME
Close Window

1 Medical Stock to Check out if You Like Passive Income

Medical service company McKesson Corp.’s (MCK) stable earnings stream helps the company enhance shareholder value through share repurchases and dividend payments. Hence, amid the uncertainties surrounding the economy and the stock market, MCK could be an ideal pick for investors looking for passive income. Keep reading…

Healthcare service provider McKesson Corporation (MCK) has returned $1.60 billion of cash to shareholders in the first six months of the fiscal year. This included $1.50 billion of common stock repurchases and $139 million in dividend payments.

Moreover, on October 27, MCK declared a regular dividend of 54 cents per share of common stock, payable on January 3, 2023. Its annual dividend of $2.16 yields 0.55% on the current share price. It has a four-year average yield of 0.95%.

Its dividend payouts have increased at a 7.3% CAGR over the past three years and a 10.6% CAGR over the past five years. The company has grown its dividend payments for 14 consecutive years.

The stock has gained 78% over the past year and 56.8% year-to-date. It is up 14.7% over the past month to close its last trading session at $389.79. MCK is trading higher than its 50-day moving average of $359.21 and 200-day moving average of $322.78.

We think the following factors might influence MCK’s performance in the near term:

Sound Financials

For the fiscal second quarter ended September 30, MCK’s revenues increased 5.4% year-over-year to $70.16 billion. Net income attributable to MCK rose 246.8% from the prior-year quarter to $926 million. Earnings per common share attributable to MCK improved 275.4% from the same period the prior year to $6.42.

Its adjusted earnings and adjusted EPS came in at $874 million and $6.06, respectively. As of September 30, the company’s cash and cash equivalents were $2.92 billion, up 35.6% from the prior-year period.

Attractive Valuation

In terms of its forward P/E, MCK is trading at 17.68x, 30.2% lower than the industry average of 25.33x. The stock’s forward EV/Sales multiple of 0.22 is 94.3% lower than the industry average of 3.91. In terms of its forward Price/Sales, it is trading at 0.20x, 95.5% lower than the industry average of 4.39x.

Favorable Analyst Expectations

The consensus EPS estimates of $6.35 and $6.52 for the quarters ending December 2022 and March 2023 indicate 3.3% and 11.8% year-over-year increases. Likewise, the consensus EPS estimate for the fiscal year 2023 of $24.72 reflects a rise of 4.3% from the prior year.

In addition, MCK’s EPS is expected to grow 9.9% per annum over the next five years. Moreover, Street revenue estimate of $276.59 billion for fiscal 2023 indicates a 4.4% year-over-year increase.

POWR Ratings Reflect Promising Prospects

MCK’s strong fundamentals are reflected in its POWR Ratings. The stock has an overall rating of A, which equates to a Strong Buy in our proprietary rating system. The POWR Ratings are calculated by considering 118 different factors, with each factor weighted to an optimal degree.

Our proprietary rating system also evaluates each stock based on eight distinct categories. MCK has a Growth grade of A, in sync with its revenue and EPS growth at 7% and 44.3% CAGRs over the past three years, respectively.

MCK also has a B grade for Value and Sentiment, consistent with its lower-than-industry valuation multiples and favorable analyst sentiments.

In the 77-stock Medical – Services industry, it is ranked #1.

Click here to see the additional POWR Ratings for MCK (Momentum, Stability, and Quality).

View all the top stocks in the Medical – Services industry here.

Bottom Line

MCK has returned hefty amounts to its shareholders in the first half of the fiscal year. Additionally, the stock is trading above its 50-day and 200-day moving averages, indicating an uptrend. Moreover, the company’s fundamentals and earnings stream should help it continue rewarding shareholders.

Hence, MCK could be an excellent investment for generating passive income amid the current market turbulence.

How Does McKesson Corporation (MCK) Stack Up Against Its Peers?

While MCK has an overall POWR Rating of A, one might want to consider looking at its industry peers, HealthStream, Inc. (HSTM) and NextGen Healthcare, Inc. (NXGN), which also have an overall A (Strong Buy) rating.


MCK shares were unchanged in premarket trading Thursday. Year-to-date, MCK has gained 57.54%, versus a -20.73% rise in the benchmark S&P 500 index during the same period.



About the Author: Anushka Dutta

Anushka is an analyst whose interest in understanding the impact of broader economic changes on financial markets motivated her to pursue a career in investment research.

More...

The post 1 Medical Stock to Check out if You Like Passive Income appeared first on StockNews.com
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.


 

IntelligentValue Home
Close Window

DISCLAIMER

All content herein is issued solely for informational purposes and is not to be construed as an offer to sell or the solicitation of an offer to buy, nor should it be interpreted as a recommendation to buy, hold or sell (short or otherwise) any security.  All opinions, analyses, and information included herein are based on sources believed to be reliable, but no representation or warranty of any kind, expressed or implied, is made including but not limited to any representation or warranty concerning accuracy, completeness, correctness, timeliness or appropriateness. We undertake no obligation to update such opinions, analysis or information. You should independently verify all information contained on this website. Some information is based on analysis of past performance or hypothetical performance results, which have inherent limitations. We make no representation that any particular equity or strategy will or is likely to achieve profits or losses similar to those shown. Shareholders, employees, writers, contractors, and affiliates associated with ETFOptimize.com may have ownership positions in the securities that are mentioned. If you are not sure if ETFs, algorithmic investing, or a particular investment is right for you, you are urged to consult with a Registered Investment Advisor (RIA). Neither this website nor anyone associated with producing its content are Registered Investment Advisors, and no attempt is made herein to substitute for personalized, professional investment advice. Neither ETFOptimize.com, Global Alpha Investments, Inc., nor its employees, service providers, associates, or affiliates are responsible for any investment losses you may incur as a result of using the information provided herein. Remember that past investment returns may not be indicative of future returns.

Copyright © 1998-2017 ETFOptimize.com, a publication of Optimized Investments, Inc. All rights reserved.